Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 10 2022
31 10 2022
Historique:
received:
28
02
2022
accepted:
25
10
2022
entrez:
1
11
2022
pubmed:
2
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
The oncological impact of positive surgical margins (PSM) after robot-assisted partial nephrectomy (RAPN) is still under debate. We compared PSM and Negative Surgical Margins (NSM) in terms of recurrence-free survival (RFS), metastasis-free survival (MFS) and overall survival (OS) after RAPN, and we identified predictive factors of PSM. Multi-institutional study using the UroCCR database, which prospectively included 2166 RAPN between April 2010 and February 2021 (CNIL DR 2013-206; NCT03293563). Two groups were retrospectively compared: PSM versus NSM. Prognostic factors were assessed using Kaplan-Meyer curves with log-Rank test, cox hazard proportional risk model and logistic regression after univariate comparison. 136 patients had PSM (6.3%) and 2030 (93.7%) had NSM. During a median follow-up of 19 (9-36) months after RAPN, 160 (7.4%) recurrences were reported. Kaplan-Meier curves and analysis suggested that RFS, MFS and OS were not affected by a PSM (p = 0.68; 0.71; 0.88, respectively). In multivariate analysis predictors of PSM were a lower RENAL score (p = 0.001), longer warm ischemia time (WIT) (p = 0.003) and Chromophobe Renal Cell Carcinoma (chrRCC) (p = 0.043). This study found no impact of PSM on RFS, MFS or OS, and predictors of PSM were the RENAL score, WIT and chrRCC.
Identifiants
pubmed: 36316438
doi: 10.1038/s41598-022-23146-4
pii: 10.1038/s41598-022-23146-4
pmc: PMC9622828
doi:
Banques de données
ClinicalTrials.gov
['NCT03293563']
Types de publication
Clinical Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
18342Informations de copyright
© 2022. The Author(s).
Références
Clin Genitourin Cancer. 2019 Feb;17(1):e26-e31
pubmed: 30266249
J Urol. 2016 Aug;196(2):327-34
pubmed: 26907508
J Urol. 2004 Sep;172(3):863-6
pubmed: 15310984
Eur J Surg Oncol. 2020 Jul;46(7):1353-1359
pubmed: 32007380
J Endourol. 2021 Dec;35(12):1779-1784
pubmed: 34235961
Int J Clin Oncol. 2021 Apr;26(4):636-646
pubmed: 33502646
Radiographics. 2021 Sep-Oct;41(5):1408-1419
pubmed: 34388049
Am J Clin Pathol. 2015 May;143(5):645-51
pubmed: 25873497
J Urol. 2008 Jun;179(6):2158-63
pubmed: 18423758
Eur Urol Focus. 2018 Jul;4(4):608-613
pubmed: 28753862
Eur Urol. 2010 Mar;57(3):466-71
pubmed: 19359089
BJU Int. 2015 Dec;116(6):868-72
pubmed: 25753900
J Urol. 2018 Feb;199(2):393-400
pubmed: 28941919
Int J Clin Oncol. 2020 May;25(5):892-898
pubmed: 32048086
J Robot Surg. 2021 Feb;15(1):99-104
pubmed: 32358741
Int Urol Nephrol. 2016 May;48(5):681-6
pubmed: 26861062
J Endourol. 2020 Mar;34(3):304-311
pubmed: 31931607
Eur Urol. 2010 Jun;57(6):1080-6
pubmed: 20188458
Minerva Urol Nefrol. 2020 Aug;72(4):482-489
pubmed: 32298069
J Urol. 2013 Nov;190(5):1674-9
pubmed: 23764077
J Urol. 2017 Aug;198(2):289-296
pubmed: 28274620
Eur Urol. 2010 Sep;58(3):398-406
pubmed: 20633979
J Urol. 2013 Apr;189(4):1229-35
pubmed: 23085300
Curr Urol Rep. 2017 Jan;18(1):8
pubmed: 28211006
Minerva Urol Nefrol. 2020 Feb;72(1):82-90
pubmed: 31833720
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg Oncol. 2016 Dec;23(13):4277-4283
pubmed: 27411552
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
J Urol. 2017 Jun;197(6):1403-1409
pubmed: 27993666
Eur Urol Focus. 2022 Jan;8(1):210-216
pubmed: 33622625
Eur Urol. 2019 Feb;75(2):253-256
pubmed: 30243798
Urology. 2018 Oct;120:131-137
pubmed: 30053396
World J Urol. 2018 Jul;36(7):1093-1101
pubmed: 29488096
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Minerva Urol Nefrol. 2017 Dec;69(6):523-538
pubmed: 28124871
Eur Urol Open Sci. 2020 Oct 02;21:41-46
pubmed: 34337467